WO2009030747A1

WO2009030747A1 - Derivatives of n-phenylacetamide, inhibitors of the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them

Info

Publication number: WO2009030747A1
Application number: PCT/EP2008/061773
Authority: WO
Inventors: Thibaud Portal; Laurence Dumais; Jérôme AUBERT; Laurent Lamy
Original assignee: Galderma Research and Development SNC
Current assignee: Galderma Research and Development SNC
Priority date: 2007-09-06
Filing date: 2008-09-05
Publication date: 2009-03-12
Anticipated expiration: 2010-03-06
Also published as: BRPI0815455B1; BRPI0815455A8; EP2197850B1; AR068373A1; FR2920774A1; EP2197850A1; CA2698299A1; US20100247583A1; JP2010538045A; BRPI0815455B8; ES2424659T3; FR2920774B1; US8044082B2; BRPI0815455A2; BRPI0815455C1

Abstract

The present invention relates to compounds of Formula (I) : as well as the cosmetic and pharmaceutical compositions containing such a compound.

Description

DERIVATIVES OF N-PHENYLACETAMIDE, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM

The invention relates to novel derivatives of N- phenylacetamide, inhibitors of the enzyme SOAT-I

(Sterol-O-Acyl Transferase-1) , likewise named ACAT-I

(Acylcoenzyme A Cholesterol Acyl Transferase) . It

5 likewise relates to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or else additionally in cosmetic compositions and, likewise, their non-therapeutic use.

10 The compounds having an activity of the type inhibiting SOAT-I are widely described in the literature as having activities in the regulation of biological processes involving cholesterol and its derivatives. These properties confer to this class of compounds a great

15 potential m the treatment or the prevention of numerous pathologies, and more particularly m dermatology and in cardiovascular diseases or complaints of the central nervous system. The majority of the biological effects of the inhibitors of SOAT-I

20 are mediated by the prevention of the synthesis of esters of cholesterol by the enzyme SOAT-I. Among the documents of the prior art describing molecules inhibiting SOAT-I, it is possible to mention, for example, WO96/10559, EP0370740, EP0424194, US4623663,

25 EP0557171, US5003106, EP0293880, EP0433662 and US5106873, which describe the compounds allowing arteriosclerosis or hypercholesterolemia to be treated. The therapeutic potential of inhibitors of SOAT-I m the treatment of cardiovascular diseases and,

30 in particular, of hypercholesterolemia and of arteriosclerosis is likewise described by Kharbanda R. K. et al., m Circulation, 2005, 11, 804. The potential of inhibitors of SOAT-I for the treatment of AlzheimeR's disease has likewise been reported in the

35 literature, for example, by Puglielli, L. et al., m Nature Neurosciences 2003, 6 (4), 345.

The patents US613326, US6271268 and WO2005034931 describe, with respect thereto, compounds which are inhibitors of SOAT-I allowing the production of sebum to be inhibited. In the field of dermatology in particular, it is particularly advantageous to prevent the excessive production of sebum and all the associated conditions. Sebum is produced by the sebaceous gland. The greater concentration of sebaceous glands is situated on the face, the shoulders, the back and the scalp. The sebum is secreted on the surface of the skin, where it plays a major physiological role, linked to the maintenance of the cutaneous barrier and of a microenvironment allowing the regulation of the bacterial flora and cutaneous fungus.

The hyperproduction of sebum is, most often, associated with a skin or a scalp of greasy appearance, a cause of discomfort and a degraded appearance. In addition, the hyperproduction of sebum can breed seborrhoeic dermatitis and is associated with an increased incidence or severity of acne. The esters of cholesterol produced in the sebaceous gland by SOAT-I are one of the components of sebum, among several classes of lipids including the triglycerides, the esters of waxes and the squalenes, as described by Nikkari, T., in J Invest Derm 1974, 62, 257. The inhibition of this enzyme or other acyltransferases can thus allow the production of sebum to be inhibited. The patent US6133326 describes, in particular, the inhibition of the sebum by inhibitors of ACAT-I

(likewise named SOAT-I) . Nevertheless, to date, no treatment employing such inhibitors is available commercially. The only treatments allowing the disorders linked to hyperseborrhoea to be remedied or relieved are systemic hormonal treatments or systemic treatment with 13-cis-retinoic acid, treatments whose secondary effects considerably limit their field of application. There thus exists a clear cosmetic and medical need for the treatment of complaints and pathologies linked to the hyperproduction of sebum. In this context, the present invention intends to provide novel derivatives of N-phenylacetamide which are powerful inhibitors of the enzyme SOAT-I.

The subject of the invention is novel derivatives of N- phenylacetamide, inhibitors of the enzyme SOAT-I, which correspond to the following general formula (I) :

in which:

- Y represents C(O) or CH₂,

- R₁ represents a (Ci-C₆) alkyl group,

R₂ represents a hydrogen, chlorine, fluorine or bromine atom, or a (Ci-C₆) alkyl group,

- R₃ represents a hydrogen atom, a (Ci-C₆) alkyl group, or a -WNR₆R₇ group with W representing C(O), C(S) or CH₂, R₆ representing a hydrogen atom or a (Ci-C₆) alkyl group and R₇ representing a hydrogen atom, a cycloalkyl group or a phenyl group,

- R₄ and R' ₄ are identical and represent a (Ci-C₆) alkyl group or else R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cycloalkyl group, - R₅ represents a group chosen from amongst:

- an unsubstituted phenyl group or a phenyl group substituted by one to three identical or different substituents chosen from amongst the atoms fluorine, chlorine, iodine or bromine, and the groups (Ci-C₆) alkyl, hydroxymethyl, mono-, di- or trifluoromethyl, hydroxyl, phenyl, 2-pyridyl, 3- pyridyl or 4-pyridyl, (Ci-C₆) alkoxy, phenoxy, benzyloxy, mono-, di- or trifluoromethoxy,

- a (Ci-Ci₂) alkyl group, optionally substituted by one or more hydroxyl groups, or fluorine, chlorine, iodine or bromine atoms,

- a cycloalkyl group or a - (CH₂) _m-cycloalkyl group in which m is equal to 1, 2 or 3,

- an aralkyl group - (CH₂) _n~Ar with n equal to 1, 2 or 3 and Ar representing an unsubstituted phenyl group, unsubstituted naphthyl, or a phenyl group substituted by one to three identical or different substituents chosen from amongst the atoms fluorine, chlorine, iodine or bromine, and the groups (Ci-C₆) alkyl, hydroxymethyl, mono-, di- or trifluoromethyl, hydroxyl, phenyl, 2-pyridyl, 3- pyridyl or 4-pyridyl, (Ci-C₆) alkoxy, phenoxy, benzyloxy, mono-, di- or trifluoromethoxy, as well as their pharmaceutically acceptable salts, solvates or hydrates and their conformers or rotamers .

Alkyl group is understood as meaning a saturated, linear or branched hydrocarbon chain. (Ci-Ci₂) alkyl is understood as meaning an alkyl chain comprising from 1 to 12 carbon atoms.

(Ci-C₆) alkyl is understood as meaning an alkyl chain comprising from 1 to 6 carbon atoms. By way of example of (Ci-C₆) alkyl, mention may be made of the groups methyl, ethyl, n-propyl, isopropyl, n-butyl, tert- butyl, sec-butyl, pentyl, hexyl .

(Ci-C₄) alkyl is understood as meaning an alkyl chain comprising from 1 to 4 carbon atoms. By way of example of (Ci-C₄) alkyl, mention may be made of the groups methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl and sec-butyl .

(Ci-C₆) alkoxy designates an -O- (Ci-C₆) alkyl group.

Phenoxy designates an -O-phenyl group.

Cycloalkyl group designates a cyclic, saturated hydrocarbon chain, comprising from 3 to 7 carbon atoms. By way of example of a cycloalkyl group, mention may be made of the groups cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

Preferred compounds of formula (I) defined above are those in which:

- Y represents C(O) or CH₂,

- R₁ represents a (Ci-C₄) alkyl group,

R₂ represents a hydrogen, fluorine, chlorine or bromine atom or a (Ci-C₄) alkyl group,

- R₃ represents a hydrogen atom, a (Ci-C₄) alkyl group, or a -WNR₆R₇ group with W representing C(O), C(S) or CH₂, R₆ representing a hydrogen atom or a (Ci-C₄) alkyl group and R₇ representing a cycloalkyl group comprising 5, 6 or 7 carbon atoms or a phenyl group,

- R₄ and R' ₄ are identical and represent a (Ci-C₄) alkyl group or else R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cycloalkyl group comprising 5, 6 or 7 carbon atoms, - R₅ represents a group chosen from amongst: an unsubstituted phenyl group or phenyl substituted by one, two or three identical or different substituents chosen from amongst the atoms fluorine, chlorine and bromine and the groups (Ci-C₄) alkyl, trifluoromethyl, hydroxymethyl, mono-, di- and trifluoromethoxy, (Ci-C₄) alkoxy, phenoxy, benzyloxy, phenyl, 2-pyridyl, 3-pyridyl and 4- pyridyl,

- a (C₂-Ci₂) alkyl group, optionally substituted by one or more hydroxyl groups or fluorine atoms,

- a cycloalkyl group or a -CH₂-cycloalkyl group,

- an aralkyl group - (CH₂) _n-Ar in which n is equal to 1, 2 or 3 and Ar represents an unsubstituted phenyl group or phenyl monosubstituted by a (Ci- C₄) alkyl, trifluoromethyl or (Ci-C₄) alkoxy group, or a fluorine, chlorine or bromine atom, as well as their pharmaceutically acceptable salts, solvates or hydrates and their conformers or rotamers . According to the present invention, amongst the compounds of formula (I) such as defined above, particularly preferred compounds are those which have one or a combination of the following characteristics: - Ri represents a methyl, ethyl or isopropyl group,

- R₂ represents a chlorine or bromine atom or a methyl, ethyl, isopropyl or tert-butyl group,

- R₃ represents a hydrogen atom, a methyl group or a -WNR₆R₇ group with W representing C (O) , R₆ representing a methyl group and R₇ representing a cyclohexyl group or a phenyl group,

- R₄ and R' ₄ are identical and represent an ethyl or n- propyl group, or else R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cyclopentyl, cyclohexyl or cycloheptyl group,

- R₅ represents a group chosen from amongst: an unsubstituted phenyl group or phenyl substituted by one, two or three identical or different substituents chosen from amongst the atoms chlorine and fluorine, and the groups methyl, ethyl, n-butyl, trifluoromethyl, hydroxymethyl, di- and trifluoromethoxy, methoxy, phenoxy and benzyloxy, - a sec-butyl, n-propyl, n-butyl, n-pentyl, 2,2- dimethylpropyl, n-hexyl, n-heptyl, n-octyl, n- nonyl, an n-butyl group substituted in position 4 by three fluorine atoms, an n-propyl group substituted in position 3 by three fluorine atoms, an n-butyl group substituted in position 4 by a hydroxyl group, or an n-propyl group substituted in position 3 by a hydroxyl group, a -CH₂-cyclopropyl, -CH₂-cyclohexyl, cyclopentyl, cyclohexyl or cycloheptyl group, - a group - (CH₂) _n-Ar with n equal to 1 or 2 and Ar representing an unsubstituted phenyl group or phenyl monosubstituted, preferably in the meta or para position, by a methyl, trifluoromethyl or methoxy group or a fluorine atom. According to the present invention, amongst the compounds of formula (I) such as defined above, more particularly preferred compounds are those which have one or a combination of the following characteristics, when one does not exclude the other: Ri = R₂ = iPr, R₃ = H;

- R₁ = R₂ = Et, R₃ = H;

R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cyclopentyl or cyclohexyl group;

- R₅ represents an unsubstituted phenyl group or phenyl substituted, in the meta or para position, by a chlorine or fluorine atom, or by a methyl or methoxy group;

- Y = C (O) .

The compounds below, as well as their pharmaceutically acceptable salts, solvates and hydrates and their conformers or rotamers are particularly preferred:

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro [4.4 ] non-3-yl) acetamide, compound (I.I) With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = Ph

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.2) With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = Ph

- N- (Cyclohexyl) -4- [2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro[4.5]dec-3-yl] -acetylamino] -3, 5, N- trimethylbenzamide, compound (1.3)

With Y = C (O) ; R₁ = R₂ = Me; R₃ = WNR₆R₇; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = Ph; R₆ = Me; R₇ = cyclohexyl; W = C (O)

- 4- [2- (2, 4-Dioxo-l-phenyl-l, 3-diazaspiro [4.5] dec-3- y] acetylamino] -3, 5, N-trimethyl-N-phenylbenzamide, compound (1.4)

With Y = C (O) ; R₁ = R₂ = Me; R₃ = WNR₆R₇; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = Ph, R₆ = Me; R₇ = Ph; W = C (0)

- N- (2, 6-Diisopropylphenyl) -2- (4-oxo-l-phenyl-l, 3- diazaspiro [4.5] dec-3-yl) -acetamide, compound (1.5) With Y = CH₂; Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = Ph

- 2- [1- (4-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, compound (1.6)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Cl-Ph

-N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluorophenyl) -2, 4- dioxo-l,3-diazaspiro-[4.5]dec-3-yl] acetamide, compound (1.7)

With Y = C(O); R_x = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-F-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-methoxyphenyl) -2, 4- dioxo-l, 3-diazaspiro [4.5]dec-3-yl] ace t amide, compound (1.8)

With Y = C (O) ; R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-MeO- Ph

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro [4.6] undec-3-yl) acetamide, compound (1.9)

With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cycloheptyl; R₅ = Ph

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-p-tolyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.10) With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H R₄ and R' ₄ are bonded to one another to form a cycloheptyl; R₅ = 4-Me- Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-fluorophenyl) -2, 4- dioxo-l, 3-diazaspiro [4.5]dec-3-yl] ace t amide, compound

(I. H)

With Y = C (O) ; R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3-F-Ph

- 2- [1- (3-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, compound (1.12) With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3-C1- Ph

- 2- (l-Cyclopentyl-2, 4-dioxo-l,3-diazaspiro[4.5]dec-3- yl) -N- (2, 6-diisopropyl-phenyl) acetamide, compound (1.13)

With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = cyclopentyl

- 2- [ l-Cyclohexyl-2, 4-dioxo-l,3-diazaspiro[4.5]dec-3- yl) -N- (2, 6-diisopropyl-phenyl) acetamide, compound (1.14)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = cyclohexyl

- 2- [ 1- (Cycloheptyl-2, 4-dioxo-l,3-diazaspiro[4.5]dec-3- yl) -N- (2, 6-di-isopropylphenyl) acetamide, compound (1.15) With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = cycloheptyl

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-m-tolyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.16) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3-Me- Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluorophenyl) -2, 4- dioxo-l,3-diazaspiro[4.4]non-3-yl] acetamide, compound (1.17)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-F- Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-methoxyphenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.18)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3-MeO- Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (2-fluorophenyl-2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.19) With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2-F-Ph

- 2- [1- (2-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, compound (1.20)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2- Cl-

Ph

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-o-tolyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.21) With Y = C(O); Ri = R_{2 =} iPr; R ₌ H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2-Me-Ph

- 2- (1 -Benzyl-2, 4-dioxo-l, 3-diazaspiro [4.5] dec-3-yl) -N- (2, 6-diisopropyl-phenyl) acetamide, compound (1.22) With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n- Ar; n = 1; Ar = Ph

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenethyl- 1, 3-diazaspiro [4.5] dec-3-yl) acetamide, compound (1.23) With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n~ Ar; n = 1; Ar = Ph

- 2- [1- (4-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro[4.4]non-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, compound (1.24)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-C1-

Ph

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-propyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.25) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n-Pr

- 2- (1 -Butyl-2, 4-dioxo-l, 3-diazaspiro [4.5] dec-3-yl) -N- (2, 6-diisopropyl-phenyl) acetamide, compound (1.26) With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n-Bu

- 2- (l-Cyclohexylmethyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl)-N-(2,6-di- isopropylphenyl) acetamide, compound (1.27) With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = CH₂- cyclohexyl

- N- (2, 6-Diisopropylphenyl) -2- (l-isobutyl-2, 4-dioxo- 1, 3-diazaspiro [4.5] dec-3-yl) acetamide, compound (1.28)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2-Me- Pr

- N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-pentyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.29) With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n- pentyl

- N- (2, 6-Diisopropylphenyl) -2- (l-heptyl-2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.30) With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n- heptyl

- 2- (l-Cyclopropylmethyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl)-N-(2,6-di- isopropylphenyl) acetamide, compound (1.31)

With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = CH₂- cyclopropyl

- N- (2, 6-Diisopropylphenyl) -2- [1- (2, 2-dimethylpropyl) -

2,4-dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.32)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2,2- dimethylpropyl

- N- (2, 6-Diisopropylphenyl) -2- [1- (2-methoxyphenyl) -2, 4- dioxo-1, 3-diazaspiro [4.5] dec-3-yl ] acetamide, compound (1.33)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2-MeO- Ph

- N- (2, 6-Diisopropylphenyl) - 2- (2, 4-dioxo-l-p-tolyl- 1 , 3-diazaspiro [ 4.4 ] non-3-yl) acetamide, compound (1.34) With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-Me- Ph

- N- (2, 6-Diisopropylphenyl) -2- (l-hexyl-2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.35) With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n- hexyl

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-ethylphenyl) -2, 4- dioxo-1, 3-diazaspiro[ 4.5] dec-3-yl] acetamide, compound (1.36)

With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Et- Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-ethylphenyl) -2, 4- dioxo-l,3-diazaspiro[4.4]non-3-yl] acetamide, compound (1.37) With Y = C(O); R₁ = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-Et- Ph

- 2- [1- (4-Butylphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, compound (1.38)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Bu-

Ph

-2- (4, 4-Diethyl-2, 5-dioxo-3-p-tolylimidazolidin-l-yl) - N- (2, 6-diisopropyl-phenyl) acetamide, compound (1.39) With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ = R' ₄ = Et; R₅ 4-Me-Ph

- 2- [1- (4-Butylphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.4]non-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, compound (1.40)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-Bu- Ph

- 2- [1- (4-Benzyloxyphenyl) -2, 4-dioxo-l, 3- diazaspiro [4.4]non-3-yl] -N- (2, 6-di- isopropylphenyl) acetamide, compound (1.41)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-

BnO-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (4- hydroxymethylphenyl) -2, 4-dioxo-l, 3-diazaspiro[ 4.5] dec-

3-yl] acetamide, compound (1.42)

With Y = C(O); Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4- hydroxymethyl-Ph

- N- (2, 6-Diisopropylphenyl) -2- (l-nonyl-2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.43) With Y = C (O) ; Ri = R₂ = iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n- nonyl

- N- (2, 6-Diisopropylphenyl) -2- (l-octyl-2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.44) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n- octyl

- 2-(2, 4-Dioxo-l-p-tolyl-1,3-diazaspiro[4.5] dec-3-yl )- N- (2, 4, 6-trimethyl-phenyl) acetamide, compound (1.45) With Y = C(O); Ri = R_{2 =} R₃ = Me; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me-Ph

- N- (2-Chloro-6-methylphenyl) -2- (2, 4-dioxo-l-p-tolyl- 1, 3-diazaspiro [4.5] dec-3-yl) acetamide, compound (1.46) With Y = C(O); Ri = Me; ₌ R_{2 =} Cl; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me-Ph

- 2- (2, 4-Dioxo-l-p-tolyl-l, 3-diazaspiro [4.5] dec-3-yl) - N- (2-isopropyl-6-methylphenyl) acetamide, compound (1.47)

With Y = C(O); Ri = Me; R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me- Ph

- N- (2, 6-Diethylphenyl) -2- (2, 4-dioxo-l-p-tolyl-l, 3- diazaspiro [4.5] dec-3-yl) -acetamide, compound (1.48) With Y = C(O); R₁ = R₂ = Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me- Ph

- N- (2, 6-Diethyl-4-methylphenyl) -2- (2, 4-dioxo-l-p- tolyl-l, 3-diazaspiro [4.5] dec-3-yl) acetamide, compound (1.49)

With Y = C(O); R₁ = R_{2 =} Et; R₃ = Me; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me- Ph

- N- (2-Chloro-4, 6-dimethylphenyl) -2- (2, 4-dioxo-l-p- tolyl-l,3-diazaspiro[4.5]dec-3-yl) acetamide, compound (1.50)

With Y = C(O); R₁ = Me; R_{2 =} Cl; R₃ = Me; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me- Ph

- N- (2, 6-Diethylphenyl) -2- (2, 4-dioxo-l-phenethyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.51) With Y = C(O); R₁ = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n- Ar; n = 2; Ar = Ph

- N- (2-Bromo-4, 6-dimethylphenyl) -2- (2, 4-dioxo-l-p- tolyl-1, 3-diazaspiro[4.5] dec-3-yl) acetamide, compound (1.52)

With Y = C(O); R₁ = Me; R_{2 =} Br; R₃ = Me; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me- Ph

- N- (2-tert-Butyl-6-methylphenyl) -2- (2, 4-dioxo-l-p- tolyl-1, 3-diazaspiro [4.5] dec-3-yl) acetamide, compound (1.53)

With Y = C(O); Ri = Me; R_{2 =} tBu; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R5 = 4-Me- Ph

- N- (2, 6-Diethylphenyl) -2- [1- (4-ethylphenyl) -2, 4-dioxo- 1, 3-diazaspiro [4.5] dec-3-yl] acetamide, compound (1.54) With Y = C(O); Ri = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Et- Ph

- N- (2, 6-Diethylphenyl) -2- (2, 4-dioxo-l-propyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.55) With Y = C(O); Ri = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R5 = n-Pr

- 2- [1- (4-Butylphenyl) -2, 4-dioxo-l,3- diazaspiro[4.5]dec-3-yl]-N-(2, 6-diethy1- phenyl) acetamide, compound (1.56)

With Y = C(O); R₁ = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Bu- Ph

- N- (2, 6-Diethylphenyl) -2- [1- (4-ethylphenyl) -2, 4-dioxo- 1, 3-diazaspiro [4.4 ] non-3-yl] acetamide, compound (1.57) With Y = C(O); Ri = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-Et- Ph

- N- (2, 6-Diethylphenyl) -2- (l-heptyl-2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.58) With Y = C(O); R₁ = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = n- heptyl

- N- (2, 6-Diethylphenyl) -2- (l-isobutyl-2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.59)

With Y = C(O); Ri = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R5 = 2-Me- Pr

- 2- [1- (4-Benzyloxyphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, compound (1.60) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R5 = 4-BnO- Ph

- 2- [1- (4-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro [4.4] non-3-yl] -N- (2, 6-di- ethylphenyl) acetamide, compound (1.61)

With Y = C(O); R₁ = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclopentyl; R₅ = 4-C1- Ph

- 2- [ 1- (4-Benzyloxyphenyl) -2 , 4-dioxo-l , 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- ethylphenyl) acetamide, compound (1.62)

With Y = C(O); Ri = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R5 = 4-BnO- Ph

- 2- (1 -Benzyl-2, 4-dioxo-l, 3-diazaspiro [4.5] dec-3-yl) -N- (2, 6-diethylphenyl) -acetamide, compound (1.63)

With Y = C(O); Ri = R_{2 =} Et; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) n- Ar; n = 1; Ar = Ph

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4- trifluoromethylphenyl) -1, 3-diazaspiro [4.5] dec-3- yl] acetamide, compound (1.64) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-CF₃- Ph

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (3- trifluoromethylphenyl) -l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.65)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3-CF₃- Ph

- N- (2 , 6-Diisopropylphenyl) -2- [2 , 4-dioxo-l- (2- trifluoromethylphenyl) -l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.66)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2-CF₃- Ph

- 2- [1- (4-Difluoromethoxyphenyl) -2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl] -N- (2,6- diisopropylphenyl) acetamide, compound (1.67)

With Y = C(O) ; Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-

CHF₂O-Ph

- 2- [1- (4-Trifluoromethoxyphenyl) -2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl] -N- (2, 6-diisopropyl- phenyl) acetamide, compound (1.68)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-CF₃O- Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3, 4-dimethylphenyl) - 2,4-dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.69) With Y = C (O) ; Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3, 4- diMe-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (2, 4-dimethylphenyl) - 2,4-dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.70)

With Y = C (O) ; Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2, 4- diMe-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-fluoro-4- methylphenyl) -2,4-dioxo-l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.71)

With Y = C (O) ; R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3-F-4- Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-methyl-3- trifluoromethylphenyl) -2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl] acetamide, compound (1.72) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-Me- 3-CF₃-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3, 5-difluoro-4- methylphenyl) -2,4-dioxo-l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.73)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3,5- diF-4-Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (2-fluoro-4- methylphenyl) -2,4-dioxo-l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.74)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 2-F-4-

Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluoro-3- methylphenyl) -2,4-dioxo-l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.75)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-F-3- Me- Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-chloro-3- methylphenyl) -2,4-dioxo-l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.76)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-C1-

3-Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (3- phenoxyphenyl) -l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.77)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-

PhO-Ph

- N- (2, 6-Diisopropylphenyl) -2- (2, 5-dioxo-4, 4-dipropyl- 3-p-tolylimidazolidin-l-yl) acetamide, compound (1.78) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ = R' ₄ = nPr; R₅ 4-Me-Ph

- 2- (4, 4-Dibutyl-2, 5-dioxo-3-p-tolylimidazolidin-l-yl) N- (2, 6-diisopropyl-phenyl) acetamide, compound (1.79) With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ = R' ₄ = nBu; R₅ 4-Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4, 4, 4- trifluorobutyl) -l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.80)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4,4,4- FFF-nBu

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4,4,4- trifluoropropyl)-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.81)

With Y = C (O) ; Ri = R_{2 =} iPr ; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl ; R₅ = 3 , 3 , 3-

FFF-nPr

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-hydroxypropyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.82)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 3-0H- nPr

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-hydroxybutyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.83)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = 4-0H- nBu

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluorobenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.84)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n- Ar; n = 1; Ar = 4F-Ph

(1.84)

- N- (2, 6-Diisopropylphenyl) -2- [1- (4-methylbenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.85)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n~ Ar; n = 1; Ar = 4Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4- trifluoromethylbenzyl) -l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.86)

With Y = C (O) ; Ri = R_{2 =} iPr ; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl ; R₅ = (CH₂ ) _n-

Ar ; n = 1 ; 4CF₃-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-methylbenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.87)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n~ Ar; n = 1; Ar = 3Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-fluorobenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.88)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n- Ar; n = 1; Ar = 3F-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (3-methoxybenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.89)

With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n- Ar; n = 1; Ar = 3MeO-Ph

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (3- trifluoromethylbenzyl) -l,3-diazaspiro[4.5]dec-3- yl] acetamide, compound (1.90)

Ar ; n = 1 ; Ar = 3CF₃-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (2-methylbenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.91)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n~ Ar; n = 1; Ar = 2-Me-Ph

- N- (2, 6-Diisopropylphenyl) -2- [1- (2-fluorobenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, compound (1.92)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n- Ar; n = 1; Ar = 2F-Ph

- N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (2- trifluoromethylbenzyl) -l,3-diazaspiro[4.5]dec-3- yl]acetamide compound (1.93)

With Y = C(O); Ri = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = (CH₂) _n~

Ar; n = 1; Ar = 3CF₃-Ph

The salts of the compounds according to the invention are prepared according to techniques well known to the person skilled in the art. The salts of the compounds of formula (I) according to the present invention comprise those with inorganic or organic acids which allow a suitable separation or a crystallization of the compounds of formula (I), as well as pharmaceutically acceptable salts. As an appropriate acid, it is possible to mention: picric acid, oxalic acid or an optically active acid, for example a tartaric acid, a dibenzoyltartaric acid, a mandelic acid or a camphorsulphonic acid, and those which form physiologically acceptable salts, such as the hydrochloride, the hydrobromide, the sulphate, the hydrogensulphate, the dihydrogenphosphate, the maleate, the fumarate, the 2-naphthalenesulphonate and the para- toluenesulphonate, the hydrochloride being preferred.

The solvates or hydrates may be obtained directly at the end of the synthesis process, the compound (I) being isolated in the form of a hydrate, for example a mono- or hemihydrate or a solvate of the reaction or purification solvent.

The compounds of formula (I) can be purified according to any conventional purification technique, for example by crystallization or purification by column chromatography .

When a compound of formula (I) according to the invention has one or more asymmetric carbons, the optical isomers of this compound are integral parts of the invention. The compound of formula (I) can thus be found in the form of a pure isomer or of a mixture of isomers in any proportion.

Conformers are understood as meaning an element of a set of conformational stereoiomers of which each is characterized by a conformation corresponding to a distinct minimum potential energy of the molecular entity.

Rotamer is understood as meaning an element of an assembly of conformers resulting from a restricted rotation around a single bond.

The compounds of formula (I) according to the invention can be prepared according to SCHEME 1 below, in which Y, Ri, R₂, R3, R4, R4' and R₅ are as defined for the compounds of formula (I) : SCHEME 1

The compounds of formula (I) can be prepared by addition of the imidazolidinones or imidazolidinediones of formula (1) to the chloroacetamides of formula (2) in the presence of a base, as SCHEME 1 describes and by analogy, for example, with the reactions described in Dunbar, B. et al . , Pharmazie 2005, 51 [I), 438, Pinza, M. et al., J Med Chem 1993, 36 (26), 4214, Coudert, P. et al., Pharm Acta HeIv. 1991, 66 (5-6), 155 or Usifoh, C. 0.; Arch Pharm, 2001, 334 (11), 366.

The imidazolidinones or imidazolidinediones of general formula 1 can be prepared according to SCHEME 2 below, in which Y, R₄, R' ₄ and R₅ are as defined for the compounds of formula (I) :

SCHEME 2

The compounds of formula (1) are obtained starting from ketones of formula (3) . The latter are first reacted with the amines or anilines of formula (4) in the presence of trimethylsilyl cyanide, in order to give the nitrile compounds of formula (5) , according, for example, to the conditions described in Matsumoto, K. et al., HeIv ChIm Acta 2005, 88 [I) , 1734-1753 or Nieto, M. J. et al . , J Comb Chem 2005, 7 (2), 258-263. The hydrolysis of the nitrile function in the presence of acid, for example, under the conditions described in Beths R. L. et al., J. Chem. Soc, 1921, 1310 allows the primary amides of the formula (6) to be obtained. The cyclization, either in the presence of formaldehyde as described in Fueloep, F et al . Pharmazie 1992, 41 (3), 168 or Chen, F. -L.; Sung, K.; J Heterocycl Chem 2004, 41 (5), 697 in the case where Y = CH₂, either in the presence of an appropriate aryl isocyanate as described in Papadopoulos, E. P.; J Org Chem 1977, 42, 3925 for the case where Y = C(O) allows the imidazolidinones or the imidazolidinediones respectively of formula (1) to be obtained.

The chloroacetamides of general formula (2) can be prepared according to an amidification reaction starting from anilines of formula (7) in the presence of a base and chloroacetyl chloride, for example, as described in Davion, Y. et al . , Heterocycles 2004, 63 (5), 1093 or Juaristy, E. et al., J Org Chem 1999, 64 (8), 2914, as illustrated in SCHEME 3 below in which R₁, R₂ and R₃ are such as defined for the compounds of formula (I) :

SCHEME 3

- A A -

The anilines (7) are commercial compounds or are prepared according to techniques well known to the person skilled in the art.

The functional groups optionally present in the reaction intermediates used in the process can be protected, either in a permanent manner or in a temporary manner, by protective groups which ensure an unequivocal synthesis of the expected compounds. The protection and deprotection reactions are carried out according to techniques well known to the person skilled in the art. A temporary protective group of amines, of alcohols or of carboxylic acids is understood as meaning the protective groups such as those described in "Protective Groups in Organic Chemistry", ed McOmie J. W. F., Plenum Press, 1973, in "Protective Groups in Organic Synthesis" 2nd edition, Greene T. W. and Wuts P. G. M., ed John Wiley and Sons, 1991 and in "Protecting Groups", Kocienski P. J., 1994, Georg Thieme Verlag.

The compounds (I) according to the invention, as well as their pharmaceutically acceptable salts, solvates and/or hydrates, have inhibitory properties on the enzyme SOAT-I. This inhibitory activity on the enzyme

SOAT-I is measured according to a primary enzymatic test HepG2, as described in Example 64. The preferred compounds according to the present invention have a concentration allowing 50% of the response of the enzyme (IC₅₀) to be inhibited at less than or equal to

1000 nM, preferably at less than or equal to 300 nM, advantageously at less than or equal to 100 nM, or even at 50 nM.

A subject of the present invention is likewise, by way of medicament, the compounds of formula (I) such as described above, as well as their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and/or hydrates.

A subject of the present invention is the use of at least one compound of formula (I), and also its salts, pharmaceutically acceptable solvates and/or hydrates, for the manufacture of a medicament in order to prevent and/or to treat the disorders of the sebaceous gland such as hyperseborrhoea, acne, seborrheic dermatitis, atopic dermatitis or rosacea, ocular pathologies such as ocular rosacea, disorders of the meibomian gland, such as blepharitis, meibomitis, chalazion, dry eye, conjunctivitis or keratoconjunctivitis, or even pathologies such as hypercholesterolemia, arteriosclerosis or Alzheimer's disease. The compounds according to the invention are particularly suited to the manufacture of a pharmaceutical composition intended for the treatment of acne. The compounds according to the invention are thus suitable for use in the treatment of the pathologies listed above.

A subject of the present invention is likewise a pharmaceutical or cosmetic composition comprising, in a physiologically acceptable carrier, at least one compound of formula (I) such as defined above, or one of its salts, pharmaceutically acceptable solvates and/or hydrates. The compositions according to the invention thus comprise a physiologically acceptable carrier or at least one physiologically or pharmaceutically acceptable excipient, chosen according to the cosmetic or pharmaceutical form desired and the chosen mode of administration.

Carrier or physiologically acceptable medium is understood as meaning a carrier compatible with the skin, the mucosa and/or the skin appendages.

The administration of the composition according to the invention can be effected by the enteral, parenteral, rectal, topical or ocular route. Preferably, the pharmaceutical composition is packaged in a form suitable for application by the topical route.

By the enteral route, the composition, more particularly the pharmaceutical composition, can be present in the form of tablets, of capsules, of coated tablets, of syrups, of suspensions, of powders, of granules, of emulsions, of microspheres or nanospheres or lipid or polymeric vesicles allowing controlled liberation. By the parenteral route, the composition can be present in the form of solutions or suspensions for perfusion or for injection.

The compounds according to the invention contain a compound according to the invention in sufficient quantity to obtain the therapeutic, prophylactic or cosmetic effects desired. The compounds according to the invention are generally administered in a daily dose of approximately 0.001 mg/kg to 100 mg/kg of body weight, in 1 to 3 doses. The compounds are used by the systemic route at a concentration generally between 0.001 and 10% by weight, preferably between 0.01 and 2% by weight, with respect to the weight of the composition.

By the topical route, the pharmaceutical composition according to the invention is more particularly intended for the treatment of the skin and of the mucosa and can be present in the form of ointments, of creams, of milks, of pomades, of powders, of impregnated swabs, of syndets, of solutions, of gels, of sprays, of foams, of suspensions, of lotions, of sticks, of shampoos, or of washing bases. It can likewise be present in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or polymeric patches and hydrogels allowing controlled liberation. This composition by the topical route can be present in anhydrous form, in aqueous form - A l - or in the form of an emulsion.

The compounds are used by the topical route in a concentration generally of between 0.001 and 10% by weight, preferably between 0.01 and 2% by weight, with respect to the total weight of the composition.

The compounds of formula (I) according to the invention, as well as their salts, pharmaceutically acceptable solvates and/or hydrates, likewise find application in the cosmetic field, in particular in body and hair hygiene and more particularly in order to combat or to prevent greasy skin or greasy hair or a greasy scalp.

A subject of the invention is thus likewise the cosmetic use of a composition comprising, in a physiologically acceptable carrier, at least one of the compounds of formula (I), optionally in the form of a salt, pharmaceutically acceptable solvate and/or hydrate, for body or hair hygiene.

The cosmetic composition according to the invention containing, in a cosmetically acceptable carrier, at least one compound of formula (I) or one of its salts, pharmaceutically acceptable solvates and/or hydrates, can be present especially in the form of a cream, of a milk, of a lotion, of a gel, of an ointment, of a pomade, of suspensions of microspheres or nanospheres or lipid or polymeric vesicles, of impregnated swabs, of solutions, of sprays, of foams, of sticks, of soaps, of shampoos or of washing bases.

The concentration of compound of formula (I) in the cosmetic composition is between 0.001 and 3% by weight, with respect to the total weight of the composition.

The pharmaceutical and cosmetic compositions such as previously described can moreover contain inert, or even pharmacodynamically active, additives as far as the pharmaceutical compositions are concerned, or combinations of these additives, and especially:

- wetting agents; - taste-improving agents; preservative agents such as the esters of parahydroxybenzoic acid;

- stabilizing agents;

- humidity-regulating agents; - pH-regulating agents;

- osmotic pressure-modifying agents;

- emulsifying agents;

- UV-A and UV-B filters; antioxidants, such as α-tocopherol, butylhydroxyanisole or butylhydroxy-toluene, superoxide dismutase, ubiquinol or certain metal chelating agents;

- emollients; hydrating agents such as glycerol, PEG 400, thiamorpholinone, and its derivatives or urea; - carotenoids and, especially, β-carotene;

- α-hydroxy acids and α-ketoacids or their derivatives, such as lactic, maleic, citric, glycolic, mandelic, tartaric, glyceric and ascorbic acids, and their salts, amides or esters or β-hydroxy acids or their derivatives, such as salicylic acid as well as its salts, amides or esters.

Of course, the person skilled in the art will look to choose the possible compound (s) to add to these compositions in such a way that the properties advantageously attached intrinsically to the present invention are not, or not substantially, altered by the envisaged addition.

Furthermore, generally, the same preferences as those indicated above for the compounds of formula (I) apply mutatis mutandis to the medicaments, cosmetic, pharmaceutical and use compositions employing the compounds of the invention. By way of illustration and without any limiting character, several examples of preparation of active compounds of formula (I) according to the invention are given below, as well as results of biological activity of such compounds.

The following abbreviations are used:

Ph = phenyl; Bn = benzyl; Me = methyl; Et = ethyl; Pr = propyl; iPr = isopropyl; tBu = tert-butyl; n-Pr = n- propyl; n-Bu = n-butyl; n-Pent = n-pentyl; n-Hex = n- hexyl; n-Hept = n-heptyl; n-Oct = n-octyl; n-Non = n- nonyl; m.p. = melting point

PROCEDURES

Example 1

N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro [4.4 ] non-3-yl) acetamide, compound (I.I) With Y = C(O); R₁ = R_{2 =} iPr; R₃ = H; R₄ and R' ₄ are bonded to one another to form a cyclohexyl; R₅ = Ph

a. 2-Chloro-N- (2, 6-diisopropylphenyl) acetamide

222 ml (1.59 mol) of triethylamine are added to a solution of 300 ml (1.59 mol) of 2,6- diisopropylphenylamine (starting product 1) in 1 1 of dichloromethane . The reaction mixture is cooled to 0⁰C and then 127 ml (1.59 mol) of chloroacetyl chloride are added, drop by drop. Once the addition is finished, the ice bath is removed and the medium is stirred for 20 min. It is then poured into water and extracted with dichloromethane. The organic phases are collected and washed with water. They are dried over sodium sulphate. The solvents are evaporated. The residue is filtered on a silica cake (eluent: dichloromethane) . The filtrate is evaporated and then triturated in heptane. 345 g of 2-chloro-N- (2, 6-diisopropylphenyl) acetamide are obtained in the form of a white solid. Yield = 85%. M. p. = 146-8°C.

b . l-Phenylaminocyclopentanecarbonitrile . 2.9 ml (31.8 mmol) of aniline (starting product 2) are added to a solution of 2.6 ml (29.4 mmol) of cyclopentanone (starting product 3) in 30 ml of acetic acid at 0⁰C. The solution is stirred for 15 minutes and

4 ml (30 mmol) of trimethylsilyl cyanide are added. The reaction medium is stirred for one night at room temperature and then gently poured into an ice-cold ammonium hydroxide solution while keeping the pH basic and extracted with dichloromethane. The organic phases are collected and washed with water. They are dried over sodium sulphate. The solvents are evaporated and then the residue is chromatographed on silica gel

(heptane/ethyl acetate 90/10, v/v) . 5 g of 1- phenylaminocyclopentanecarbonitrile are obtained in the form of a clear brown oil. Yield = 91%.

c . l-Phenylaminocyclopentanecarboxylamide .

5 g (26.8 mmol) of 1-phenylaminocyclopentane- carbonitrile are dissolved in 40 ml of concentrated sulphuric acid. The reaction medium is stirred at room temperature for 48 h and then gently poured into ice and the pH is brought to 7-8 with sodium hydroxide and the mixture is extracted with ethyl acetate. The organic phases are collected and washed with water. They are dried over sodium sulphate. The solvents are evaporated and the residue is precipitated in dichloromethane and heptane. It is then filtered and dried. 4.6 g of 1-phenylaminocyclopentanecarboxylamide are obtained in the form of a white solid. Yield = 84%. M . p . = 159- 61 ° C .

d. 1-Phenyl-1 , 3-diazaspiro [4.4 ] nonane-2 , 4-dione .

360 μl (1.76 mmol) of 2, 6-diisopropylphenyl isocyanate are added to a solution of 300 mg (1.47 mmol) of 1- phenylaminocyclopentane-carboxylamide in 5 ml of toluene. The reaction medium is stirred at 200⁰C for 80 min under microwave irradiation in a sealed reactor. The toluene is evaporated and the residue is purified on silica gel (heptane and then with an increasing percentage of ethyl acetate) . 130 mg of 1-phenyl-l, 3- diazaspiro [ 4.4 ] nonane-2 , 4-dione are obtained in the form of a beige solid. Yield = 38%.

e . N- (2, 6-Diisopropylphenyl) -2- (2, 4 -dioxo- 1-phenyl-l, 3- diazaspiro[4.4]non-3-yl) acetamide

80 mg (0.57 mmol) of potassium carbonate are added to a solution of 120 mg (0.52 mmol) of 1-phenyl-l, 3- diazaspiro [ 4.4 ] nonane-2 , 4-dione and 145 mg (0.57 mmol) of 2-chloro-N- (2, 6-diisopropylphenyl) acetamide in 20 ml of dimethylformamide . The reaction medium is stirred at room temperature for 24 hours. It is then poured into water and extracted with ethyl acetate. The organic phases are collected, washed with water and dried over sodium sulphate. The solvents are evaporated. The residue is chromatographed on silica gel (heptane and then heptane/ethyl acetate 80/20, v/v) . 120 mg of N- (2, 6-diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro [4.4 ] non-3-yl) acetamide are obtained in the form of a white solid. Yield = 51%, m.p. = 275-7°C. HPLC: 96.8%; Mass = 447. 1H NMR (CDCl₃; 400 Mz) : 1.21 (s, 6H); 1.23 (s, 6H); 1.55 (m, 2H); 1.85 (m, 2H); 2.03-2.08 (m, 2H); 2.22-2.26 (m, 2H); 3.06-3.12 (m, 2H); 4.50 (s, 2H); 7.18-7.21 (m, 2H); 7.28-7.31 (m, 3H); 7.41-7.49 (m, 3H) . Examples 2 to 4 and 6 to 63

The synthesis of Examples 2 to 4 and 6 to 63 is described by the tables below. The compounds are synthesized following the same procedure, replacing the starting products 1, 2 and 3 of steps a and b of Example 1 by the products mentioned in the table below. The yields of these syntheses are homogeneous for the family of compounds considered.

- 57 -

- 58 -

Example 5

N- (2, 6-Diisopropylphenyl) -2- (4-oxo-l-phenyl-l, 3- diazaspiro [4.5] dec-3-yl) acetamide, compound (1.5) With Y = CH₂ ; Ri = R₂ = iPr; R₃ = H ; R₄ and R' _< are bonded to one another to form a cyclohexyl; R5 = Ph

a/ l-Phenylaminocyclohexanecarbonitrile .

1.4 ml (15.3 mmol) of aniline are added to a solution of 1.3 ml (12.5 mmol) of cyclohexanone in 20 ml of acetic acid at 0⁰C. The solution is stirred for 10 minutes and 1.9 ml (14.2 mmol) of trimethylsilyl cyanide are added. The reaction medium is stirred overnight at room temperature. It is then gently poured into a solution of ice-cold ammonium hydroxide, while keeping the pH basic, and extracted with dichloromethane . The organic phases are collected and washed with water. They are dried over sodium sulphate. The residue is precipitated in dichloromethane and heptane. The solid is filtered and dried. 2.2 g of 1- phenylaminocyclohexanecarbonitrile are obtained in the form of whitish crystals. Yield = 88%, m.p. = 67-9°C.

b/ l-Phenylaminocyclohexanecarboxylamide . 5 g (25 mmol) of l-phenylaminocyclohexanecarbonitrile are dissolved in 30 ml of concentrated sulphuric acid. The reaction medium is stirred at room temperature for 48 h. It is then gently poured into ice and the pH is brought to 7-8 with sodium hydroxide and the mixture is extracted with ethyl acetate. The organic phases are collected and washed with water. They are dried over sodium sulphate. The solvents are evaporated and the residue is precipitated in dichloromethane and heptane. It is then filtered and dried. 5.13 g of 1- phenylaminocyclohexanecarboxylamide are obtained in the form of a white solid. Yield = 94%, m.p. = 145-7°C.

c/ 1 -Phenyl- 1, 3-diazaspiro[4.5]decan-4-one.

300 mg (1.37 mmol) of 1- phenylaminocyclohexanecarboxylamide are dissolved in 10 ml of methanol. 3 ml of formaldehyde and a catalytic quantity of APTS are added. The reaction medium is heated at 100⁰C with microwaves for 30 min. The solvent is evaporated, and the residue is taken up with dichloromethane and washed with water. The organic phases are collected and then dried over sodium sulphate. The solvents are evaporated. The residue is chromatographed on silica gel (heptane/ethyl acetate 80/20, v/v) . 50 mg of 1-phenyl-l, 3-diaza- spiro [4.5] decan-4-one are obtained in the form of a white solid. Yield = 18%, m.p. = 193-5°C.

d/ N- (2, 6-Diisopropylphenyl) -2- (4-oxo-l-phenyl-l, 3- diazaspiro[4.5]dec-3-yl) acetamide .

72 mg (0.52 mmol) of potassium carbonate are added to a solution of 120 mg (0.52 mmol) of 1-phenyl-l, 3- diazaspiro [4.5] decan-4-one and 132 mg (0.52 mmol) of 2- chloro-N- (2, 6-diisopropylphenyl) acetamide (described in Example Ia) in 20 ml of methyl ethyl ketone. The reaction medium is stirred at room temperature for 12 hours and then for 6 h at reflux. The medium is then filtered and then the residue is chromatographed on silica gel (heptane then heptane/ethyl acetate 50/50, v/v) . 135 mg of N- (2, 6-diisopropylphenyl) -2- (4-oxo-l- phenyl-l, 3-diazaspiro[4.5]dec-3-yl) acetamide are obtained in the form of a white solid. Yield = 58%, m.p. = 251-3°C. HPLC: 98.7%; mass: 446. 1H NMR (CDCl₃, 400 Mz) : 1.20 (s, 12H); 1.36-1.37 (m, IH); 1.71-1.74 (m, 2H); 1.81-1.84 (m, 2H); 2.09-2.14 (m, 2H); 2.25-2.28 (m, 2H); 3.03-3.05 (m, 2H); 4.26- 4.27 (d, 2H); 4.90-4.91 (d, 2H); 6.97 (s, 3H); 7.19- 7.20 (m, 2H); 7.33 (m, 3H); 7.84 (s, IH) .

Example 64 : Biological tests

The compounds of formula (I) according to the invention have been subjected to a test allowing their inhibitory action with respect to the enzyme ACAT-I to be evaluated inspired by the following publication:

"Identification of ACATl- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness", J. Lipid Res. (2004) vol 45, pages 378-386.

The principle of this test is based on the employment of NBD-cholesterol, an analogue of cholesterol whose fluorescence depends on its environment. When this is present in a polar environment, it is weakly fluorescent although in a nonpolar environment it is strongly fluorescent. Free NBD-cholesterol locates itself in the cell membranes and is weakly fluorescent in this polar environment. When the NBD-cholesterol is esterified by ACAT, the ester of NBD-cholesterol locates itself in the nonpolar lipid droplets and is in that case strongly fluorescent.

The method below is applied: The HepG2 cells are incubated in the presence of NBD-cholesterol (1 μg/ml) and of the compound of formula (I) to be tested in black 96-well plates with a transparent base at a rate of 30 000 cells per well. After incubation for 6 h at 37°C, under 5% CO₂, the medium is eliminated by turning over and the cells are washed with 2 times 100 μl of PBS. After addition of 50 μl of lysis buffer (NaPO₄ 10 mM, Igepal 1%) , the plates are stirred for 5 min and read in fluorescence (excitation 490 nm, emission 540 nm) on a FUSION apparatus (Perkin-Elmer) . By way of illustration, an IC₅₀ of 3.2 nM is obtained for the compound (I.I), an IC₅₀ of 0.8 nM is obtained for the compound (1.7), an IC₅₀ of 0.2 nM is obtained for the compound (1.10), an IC₅₀ of 4.8 nM is obtained for the compound (1.14), an IC₅₀ of 5.6 nM is obtained for the compound 1.23), an IC₅₀ of 2.5 nM is obtained for the compound 1.26), an IC₅₀ of 0.7 nM is obtained for the compound 1.39), an IC₅₀ of 5.1 nM is obtained for the compound 1.46), an IC₅₀ of 5.3 nM is obtained for the compound (1.52 and an IC₅₀ of 2.7 nM is obtained for the compound (1.61^'

Example 65 : Formulations Various actual formulations based on compounds according to the invention are given below.

A-ORAL ROUTE

(a) 0.2 g tablet

-Compound (1.3) 0.01 g

-Starch 0.114 g

-Dicalcium phosphate 0.020 g

-Silica 0.020 g -Lactose 0.030 g

-Talc 0.010 g

-Magnesium stearate 0.005 g

(b) Drinkable suspension in 5 ml ampoules -Compound (I.I) 0.001 g

-Glycerol 0.500 g

-70% sorbitol 0.500 g

-Sodium saccharinate 0.010 g

-Methyl para-hydroxybenzoate 0.040 g -Flavour qs

-Purified water qsp 5 ml

B-TOPICAL ROUTE

(a) Ointment

-Compound (1.2) 0.300 g

-White petroleum jelly codex qsp 100 g ( d) Lot i on

-Compound (1.4) 0.100 g

-Polyethylene glycol (PEG 400) 69.900 g

-95% ethanol 30.000 g

(e) Hydrophobic ointment

-Compound (I.I) 0.300 g

-Isopropyl myristate 36.400 g -Silicone oil ("Rhodorsil 47 V 300") 36.400 g -Beeswax 13.600 g

-Silicone oil ("Abil 300.000 cst") qsp 100 g

(f) Non-ionic oil-in-water cream

-Compound (1.2) 1.000 g -Cetyl alcohol 4.000 g

-Glycerol monostearate 2.500 g

-PEG 50 stearate 2.500 g

-Shea butter 9.200 g

-Propylene glycol 2.000 g -Methyl para-hydroxybenzoate 0.075 g

-Propyl para-hydroxybenzoate 0.075 g

-Sterile demineralized water qsp 100 g

Claims

1. Compounds of formula (I) :

in which:

- Y represents C(O) or CH₂,

- R₁ represents a (Ci-C₆) alkyl group,

- R₂ represents a hydrogen, chlorine, fluorine or bromine atom, or a (Ci-C₆) alkyl group,

- R₄ and R' ₄ are identical and represent a (Ci-C₆) alkyl group or else R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cycloalkyl group,

- R₅ represents a group chosen from amongst:

- an aralkyl group - (CH₂) _n~Ar with n equal to 1, 2 or 3 and Ar representing an unsubstituted phenyl group, unsubstituted naphthyl, or a phenyl group substituted by one to three identical or different substituents chosen from amongst the atoms fluorine, chlorine, iodine and bromine, and the groups (Ci-C₆) alkyl, hydroxymethyl, mono-, di- or trifluoromethyl, hydroxyl, phenyl, 2-pyridyl, 3- pyridyl or 4-pyridyl, (Ci-C₆) alkoxy, phenoxy, benzyloxy, mono-, di- or trifluoromethoxy, as well as their pharmaceutically acceptable salts, solvates or hydrates and their conformers or rotamers .

2. Compounds according to Claim 1, characterized in that:

- Y represents C(O) or CH₂, - Ri represents a (Ci-C₄) alkyl group,

- R₂ represents a hydrogen, fluorine, chlorine or bromine atom or a (Ci-C₄) alkyl group,

- R₄ and R' ₄ are identical and represent a (Ci-C₄) alkyl group or else R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cycloalkyl group comprising 5, 6 or 7 carbon atoms,

- R₅ represents a group chosen from amongst:

- an unsubstituted phenyl group or phenyl substituted by one, two or three identical or different substituents chosen from amongst the atoms fluorine, chlorine and bromine and the groups

(Ci-C₄) alkyl, trifluoromethyl, hydroxymethyl, mono-, di- and trifluoromethoxy, (Ci-C₄) alkoxy, phenoxy, benzyloxy, phenyl, 2-pyridyl, 3-pyridyl and 4- pyridyl ,

- a cycloalkyl group or a -CH₂-cycloalkyl group, - an aralkyl group - (CH₂) _n-Ar in which n is equal to 1, 2 or 3 and Ar represents an unsubstituted phenyl group or phenyl monosubstituted by a (Ci- C₄) alkyl, trifluoromethyl or (Ci-C₄) alkoxy group, or a fluorine, chlorine or bromine atom.

3. Compounds according to Claim 1 or 2, characterized in that Ri represents a methyl, ethyl or isopropyl group .

4. Compounds according to one of Claims 1 to 3, characterized in that R₂ represents a chlorine or bromine atom or a methyl, ethyl, isopropyl or tert- butyl group.

5. Compounds according to one of Claims 1 to 4, characterized in that R₃ represents a hydrogen atom, a methyl group or a -WNR₆R_? group with W representing C (O) , R₆ representing a methyl group and R₇ representing a cyclohexyl group or a phenyl group.

6. Compounds according to one of Claims 1 to 5, characterized in that R₄ and R' ₄ are identical and represent an ethyl or n-propyl group, or else R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cyclopentyl, cyclohexyl or cycloheptyl group.

7. Compounds according to one of Claims 1 to 6, characterized in that R₅ represents a group chosen from amongst:

- an unsubstituted phenyl group or phenyl substituted by one, two or three identical or different substituents chosen from amongst the chlorine or fluorine atoms, and the groups methyl, ethyl, n-butyl, trifluoromethyl, hydroxymethyl, di- andd trifluoromethoxy, methoxy, phenoxy and benzyloxy,

- a sec-butyl, n-propyl, n-butyl, n-pentyl, 2,2- dimethylpropyl, n-hexyl, n-heptyl, n-octyl, n-nonyl group, an n-butyl group substituted in position 4 by three fluorine atoms, an n-propyl group substituted in position 3 by three fluorine atoms, an n-butyl group substituted in position 4 by a hydroxyl group, or an n-propyl group substituted in position 3 by a hydroxyl group,

- a -CH₂-cyclopropyl, -CH₂-cyclohexyl, cyclopentyl, cyclohexyl or cycloheptyl group,

- a group - (CH₂) _n~Ar with n equal to 1 or 2 and Ar representing an unsubstituted phenyl group or phenyl monosubstituted, preferably in the meta or para position, by a methyl, trifluoromethyl or methoxy group, or a fluorine atom.

8. Compounds according to one of Claims 1 to 7, characterized in that Ri and R₂ are identical and represent an isopropyl radical and R₃ is a hydrogen atom.

9. Compounds according to one of Claims 1 to 7, characterized in that Ri and R₂ are identical and represent an ethyl radical, and R₃ is a hydrogen atom.

10. Compounds according to one of Claims 1 to 9, characterized in that R₄ and R' ₄ are bonded to one another and form, with the carbon atom to which they are bonded, a cyclopentyl or cyclohexyl group.

11. Compounds according to one of Claims 1 to 10, characterized in that R₅ represents an unsubstituted phenyl group or phenyl substituted, in the meta or para position, by a chlorine or fluorine atom, or by a methyl or methoxy group.

12. Compounds according to one of Claims 1 to 11, characterized in that Y represents C(O) .

13. Compounds according to Claim 1 chosen from amongst the compounds below, their pharmaceutically acceptable salts, solvates, hydrates, conformers and rotamers :

-N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro[4.4]non-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-N-Cyclohexyl-4- [2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro[4.5]dec-3-yl) acetylamino] -3, 5, N- trimethylbenzamide,

-4- [2- (2, 4 -Dioxo-1 -phenyl- 1, 3-diazaspiro [4.5] dec-3- yl) acetylamino] -3, 5, N-trimethyl-N-phenylbenzamide,

-N- (2, 6-Diisopropylphenyl) -2- (4-oxo-l-phenyl-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-2- [1- (4-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluorophenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (4-methoxyphenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenyl-l, 3- diazaspiro[4.6] undec-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-p-tolyl-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (3-fluorophenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide,

-2- [1- (3-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide,

-2- (l-Cyclopentyl-2, 4-dioxo-1, 3-diazaspiro [4.5] dec-3- yl) -N- (2, 6-diisopropylphenyl) acetamide,

-2- (l-Cyclohexyl-2, 4-dioxo-1, 3-diazaspiro [4.5] dec-3- yl) -N- (2, 6-diisopropylphenyl) acetamide,

-2- (l-Cycloheptyl-2, 4-dioxo-1, 3-diazaspiro [4.5] dec-3- yl) -N- (2, 6-diisopropylphenyl) acetamide, -N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-m-tolyl-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluorophenyl) -2, 4- dioxo-l,3-diazaspiro[4.4]non-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (3-methoxyphenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (2-fluorophenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide,

-2- [1- (2-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro [4.5] dec-3-yl] -N- (2, 6-di- isopropylphenyl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-o-tolyl-l, 3- diazaspiro[ 4.5] dec-3-yl) acetamide,

-2- (1 -Benzyl-2, 4-dioxo-l, 3-diazaspiro [4.5] dec-3-yl) -N- (2, 6-diisopropylphenyl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-phenethyl-

1,3-diazaspiro [4.5] dec-3-yl) acetamide,

-2- [1- (4-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro[4.4]non-3-yl]-N-(2,6- diisopropylphenyl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-propyl-l, 3- diazaspiro[ 4.5] dec-3-yl) acetamide,

-2- (1 -Butyl-2, 4-dioxo-l, 3-diazaspiro [4.5] dec-3-yl) -N-

(2, 6-diisopropylphenyl) acetamide, -2- (l-Cyclohexylmethyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl)-N-(2, 6-diisopropylphenyl) - acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (l-isobutyl-2, 4-dioxo-l, 3- diazaspiro[ 4.5] dec-3-yl) acetamide, -N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-pentyl-l, 3- diazaspiro[ 4.5] dec-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (l-heptyl-2, 4-dioxo-l, 3- diazaspiro[ 4.5] dec-3-yl) acetamide,

-2- (l-Cyclopropylmethyl-2, 4-dioxo-l, 3- diazaspiro[4.5] dec-3-yl )-N-(2, 6-diisopropylphenyl) acetamide,

-N- (2 , 6-Diisopropylphenyl) -2- [1- (2 , 2-dimethylpropyl) -

2, 4-dioxo-l, 3-diazaspiro [4.5] dec-3-yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (2-methoxyphenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- (2, 4-dioxo-l-p-tolyl-l, 3- diazaspiro[4.4]non-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (l-hexyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (4-ethylphenyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (4-ethylphenyl) -2, 4- dioxo-l,3-diazaspiro[4.4]non-3-yl] acetamide, -2- [1- (4-Butylphenyl) -2, 4-dioxo-l, 3-diazaspiro [4.5]dec- 3-yl] -N- (2, 6-diisopropylphenyl) acetamide,

-2- (4, 4-Diethyl-2, 5-dioxo-3-p-tolylimidazolidin-l-yl) - N- (2, 6-diisopropylphenyl) acetamide,

-2- [1- (4-Butylphenyl) -2, 4-dioxo-l, 3-diazaspiro [4.4] non- 3-yl] -N- (2, 6-diisopropylphenyl) acetamide, -2- [1- (4-Benzyloxyphenyl) -2, 4-dioxo-l, 3- diazaspiro [4.4] non-3-yl] -N- (2, 6-diisopropylphenyl) acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (4- hydroxymethylphenyl) -2, 4-dioxo-l, 3-diazaspiro [4.5] dec-

3-yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (l-nonyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- (l-octyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-2- (2, 4-Dioxo-l-p-tolyl-l, 3-diazaspiro [4.5] dec-3-yl) -N- (2,4, 6-trimethylphenyl) acetamide,

-N- (2-Chloro-6-methylphenyl) -2- (2, 4-dioxo-l-p-tolyl- l,3-diazaspiro[4.5]dec-3-yl) acetamide, -2- (2, 4-Dioxo-l-p-tolyl-l, 3-diazaspiro [4.5] dec-3-yl) -N-

(2-isopropyl-6-methylphenyl) acetamide, -N- (2, 6-Diethylphenyl) -2- (2, 4-dioxo-l-p-tolyl-l, 3- diazaspiro[4.5]dec-3-yl) -acetamide,

-N- (2, 6-Diethyl-4-methylphenyl) -2- (2, 4-dioxo-l-p-tolyl- l,3-diazaspiro[4.5]dec-3-yl) acetamide,

-N- (2-Chloro-4, 6-dimethylphenyl) -2- (2, 4-dioxo-l-p- tolyl-l, 3-diazaspiro [4.5] dec-3-yl) acetamide, -N- (2, 6-Diethylphenyl) -2- (2, 4-dioxo-l-phenethyl-l, 3- diazaspiro[4.5]dec-3-yl) acetamide, -N- (2-Bromo-4, 6-dimethylphenyl) -2- (2, 4-dioxo-l-p-tolyl- l,3-diazaspiro[4.5]dec-3-yl) acetamide,

-N- (2-tert-Butyl-6-methylphenyl) -2- (2, 4-dioxo-l-p- tolyl-l,3-diazaspiro[4.5]dec-3-yl) acetamide, -N- (2, 6-Diethylphenyl) -2- [1- (4-ethylphenyl) -2, 4-dioxo- l,3-diazaspiro[4.5]dec-3-yl] acetamide,

-N- (2, 6-Diethylphenyl) -2- (2, 4-dioxo-l-propyl-l, 3- diazaspiro[4.5]dec-3-yl) acetamide,

-2- [1- (4-Butylphenyl) -2, 4-dioxo-l, 3-diazaspiro [4.5] dec- 3-yl] -N- (2, 6-diethylphenyl) acetamide,

-N- (2, 6-Diethylphenyl) -2- [1- (4-ethylphenyl) -2, 4-dioxo- l,3-diazaspiro[4.4]non-3-yl] acetamide,

-N- (2, 6-Diethylphenyl) -2- (l-heptyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl) -acetamide, -N- (2, 6-Diethylphenyl) -2- (l-isobutyl-2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl) -acetamide,

-2- [1- (4-Benzyloxyphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- isopropylphenyl) acetamide, -2- [1- (4-Chlorophenyl) -2, 4-dioxo-l, 3- diazaspiro [4.4] non-3-yl] -N- (2, 6-diethylphenyl) acetamide,

-2- [1- (4-Benzyloxyphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6-di- ethylphenyl) acetamide,

-2- (1 -Benzyl-2, 4-dioxo-l, 3-diazaspiro [4.5] dec-3-yl) -N-

(2, 6-diethylphenyl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4- trifluoromethylphenyl) -1, 3-diazaspiro [4.5] dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (3- trifluoromethylphenyl) -1, 3-diazaspiro [4.5] dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (2- trifluoromethylphenyl) -1, 3-diazaspiro [4.5] dec-3- yl] acetamide,

-2- [1- (4-Difluoromethoxyphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6- diisopropylphenyl) acetamide, - I A -

-2- [1- (4-Trifluoromethoxyphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl]-N-(2,6- diisopropylphenyl) acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (3, 4-dimethylphenyl) - 2,4-dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (2, 4-dimethylphenyl) - 2,4-dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (3-fluoro-4- methylphenyl) -2, 4-dioxo-l, 3-diazaspiro[ 4.5] dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (4-methyl-3- trifluoromethylphenyl) -2, 4-dioxo-l, 3- diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (3, 5-difluoro-4- methylphenyl) -2, 4-dioxo-l, 3-diazaspiro[ 4.5] dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (2-fluoro-4- methylphenyl) -2, 4-dioxo-l, 3-diazaspiro[ 4.5] dec-3- yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluoro-3- methylphenyl) -2, 4-dioxo-l, 3-diazaspiro[ 4.5] dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (4-chloro-3- methylphenyl) -2, 4-dioxo-l, 3-diazaspiro[ 4.5] dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (3- phenoxyphenyl) -l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- (2, 5-dioxo-4, 4-dipropyl-3- p-tolylimidazolidin-1-yl) acetamide, -2- (4, 4-Dibutyl-2, 5-dioxo-3-p-tolylimidazolidin-l-yl) - N- (2, 6-diisopropylphenyl) acetamide, -N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4,4,4- trifluorobutyl) -l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4,4,4- trifluoropropyl)-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (3-hydroxypropyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (3-hydroxybutyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (4-fluorobenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (4-methylbenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (4- trifluoromethylbenzyl) -l,3-diazaspiro[4.5]dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (3-methylbenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (3-fluorobenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (3-methoxybenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (3- trifluoromethylbenzyl) -l,3-diazaspiro[4.5]dec-3- yl] acetamide,

-N- (2, 6-Diisopropylphenyl) -2- [1- (2-methylbenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [1- (2-fluorobenzyl) -2, 4- dioxo-l,3-diazaspiro[4.5]dec-3-yl] acetamide, -N- (2, 6-Diisopropylphenyl) -2- [2, 4-dioxo-l- (2- trifluoromethylbenzyl) -l,3-diazaspiro[4.5]dec-3- yl] acetamide .

14. Compounds according to one of the preceding claims, as medicaments.

15. Pharmaceutical composition comprising, in a physiologically acceptable carrier, at least one compound according to one of Claims 1 to 13.

16. Composition according to Claim 15, characterized in that the concentration of compound (s) according to any one of Claims 1 to 13 is between 0.001 and 10% by weight with respect to the total weight of the composition .

17. Composition according to Claim 16, characterized in that the concentration of compound (s) according to any one of Claims 1 to 13 is between 0.01 and 2% by weight with respect to the total weight of the composition.

18. Cosmetic composition, characterized in that it comprises, in a physiologically acceptable carrier, at least one compound according to any one of Claims 1 to 13.

19. Composition according to Claim 18, characterized in that the concentration of compound (s) according to any one of Claims 1 to 13 is between 0.001 and 3% by weight with respect to the total weight of the composition.

20. Composition according to one of Claims 15 to 19, characterized in that it is present in a form suitable for topical application.

21. Composition according to Claim 20, characterized in that it is present in the form of a cream, of a milk, of a lotion, of a gel, of an ointment, of a pomade, of suspensions of microspheres or nanospheres or lipid or polymeric vesicles, of impregnated swabs, of solutions, of sprays, of foams, of sticks, of soaps, of shampoos or of washing bases.

22. Cosmetic use of a composition as defined in any one of Claims 18 or 19 for body or hair hygiene.

23. Use of a compound according to any one of Claims 1 to 9 in the manufacture of a medicament to prevent and/or treat disorders of the sebaceous gland such as hyperseborrhoea, acne, seborrhoeic dermatitis, atopic dermatitis, rosacea, ocular rosacea, blepharitis, meibomitis, chalazion, dry eye, conjunctivitis, keratoconjunctivitis, hypercholesterolemia, arteriosclerosis and Alzheimer's disease.

24. Use of a compound according to any one of Claims 1 to 13 for the manufacture of a medicament to treat acne.